{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Terzic V"],"funding":["Agency for Clinical Research and Biomedical Innovation","Domaine d’intérêt majeur One Health Île-de-France","European Regional Development Fund (Luxembourg)","Austrian Group Medical Tumor (Austria)","Agency for Clinical Research and Biomedical Innovation (Portugal)","Austrian Group Medical Tumor","Ministry of Health","Belgian Health Care Knowledge Centre","Ministry of Health (Portugal)","EU's Horizon 2020 Research and Innovation Program","Fonds Erasme-COVID-Université Libre de Bruxelles (Belgium)","Belgian Health Care Knowledge Centre (Belgium)","Domaine d'intérêt majeur One Health Île-de-France (France)","Merck Sharp &amp; Dohme LLC","REACTing","Fonds Erasme-COVID-Université Libre de Bruxelles","EU&apos;s Horizon 2020 Research and Innovation Program","Gilead Sciences, Inc","European Regional Development Fund"],"pagination":["382-391"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11327784"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["79(2)"],"pubmed_abstract":["<h4>Background</h4>We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with coronavirus disease 2019 (COVID-19) who received remdesivir plus standard of care (SoC) compared with SoC alone (control), as an association was noted in some cohort studies and disproportionality analyses of safety databases.<h4>Methods</h4>This post hoc safety analysis is based on data from the multicenter, randomized, open-label, controlled DisCoVeRy trial in hospitalized patients with COVID-19. Any first AE that occurred between randomization and day 29 in the modified intention-to-treat (mITT) population randomized to either remdesivir or control group was considered. Analysis was performed using Kaplan-Meier survival curves, and Kaplan-Meier estimates were calculated for event rates"],"journal":["Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"],"pubmed_title":["Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial."],"pmcid":["PMC11327784"],"funding_grant_id":["PHRC 20-0351","101015736"],"pubmed_authors":["Billard N","Thiery G","Bernard L","Lefevre B","Ribeiro JMF","Oulehri W","Tacconelli E","Burdet C","Richard JC","Bruel C","Rouveix-Nordon E","Hinschberger O","Belhadi D","Piroth L","Roncon-Albuquerque R","Mourvillier B","Goehringer F","Nseir S","Le Moing V","Textoris J","Berna M","Lamprecht B","Paiva JA","Timsit JF","Epelboin L","Klouche K","Hites M","Tacquard C","Mayaux J","Gousseff M","Roger C","Lacombe K","Delbove A","Leroy S","Mootien J","Marquette CH","Le Tulzo Y","Laviolle B","Mira JP","Kimmoun A","Jaureguiberry S","Laine F","Zerbib Y","Mekontso-Dessap A","Bani-Sadr F","Garot D","Benezit F","Cazanave C","Fougerou-Leurent C","Bouchaud O","Argaud L","Fartoukh M","Ferry T","Loubet P","Lescure FX","Yazdanpanah Y","Greil R","Pourcher V","Valour F","Pilmis B","Geri G","Chabartier C","Wattecamps G","Lanoix JP","Bouiller K","Terzi N","Murris-Espin M","Gallien S","Peiffer-Smadja N","Courjon J","Perpoint T","Egle A","Gruson D","Belkhir L","Revest M","Braz S","Stefan F","Jeanmichel V","Navellou JC","Kerneis S","Dubost C","de Gastines L","Chirouze C","Leveau B","Martin-Blondel G","Diallo A","Botelho-Nevers E","Roger PA","Aboab J","Meziani F","Joannidis M","Boutoille D","Ficko C","Gagneux-Brunon A","Staub T","Tolsma V","Lessire H","Boyer A","Delmas C","Monnet X","Andrejak C","DisCoVeRy Study Group","Dellamonica J","Launay O","Ait-Oufella H","Malvy D","Bouadma L","Molina JM","Fraipont V","Faure E","Raffi F","Senneville E","Djossou F","Robert C","Altdorfer A","Faure K","Riu-Poulenc B","Esperou H","Cabie A","Duvignaud A","Saidani N","Gaci R","Costagliola D","Terzic V","Canet E","Miantezila Basilua J","Gaborit B","Mentre F","Epaulard O","Ader F","Andreu P","Wallet F","Gibot S","Makinson A","Figueiredo S","Crockett F","Ferrane A","Le Pavec J","Martinot M","Danion F","Dechanet A","Mercier N","Bougon D","Turmel JM","Sayre N","Hansmann Y","Reuter J","Verschelden G","Bounes-Vardon F","Reignier J","Pialoux G","Couffin-Cadiergues S","Poissy J","Le Turnier P","Quenot JP","Blot M","Lachatre M","Piriou V","Sotto A","Lebeaux D"],"additional_accession":[]},"is_claimable":false,"name":"Cardiac Adverse Events and Remdesivir in Hospitalized Patients With COVID-19: A Post Hoc Safety Analysis of the Randomized DisCoVeRy Trial.","description":"<h4>Background</h4>We aimed to evaluate the cardiac adverse events (AEs) in hospitalized patients with coronavirus disease 2019 (COVID-19) who received remdesivir plus standard of care (SoC) compared with SoC alone (control), as an association was noted in some cohort studies and disproportionality analyses of safety databases.<h4>Methods</h4>This post hoc safety analysis is based on data from the multicenter, randomized, open-label, controlled DisCoVeRy trial in hospitalized patients with COVID-19. Any first AE that occurred between randomization and day 29 in the modified intention-to-treat (mITT) population randomized to either remdesivir or control group was considered. Analysis was performed using Kaplan-Meier survival curves, and Kaplan-Meier estimates were calculated for event rates","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-06-03T00:14:25.698Z","creation":"2024-11-09T15:42:55.574Z"},"accession":"S-EPMC11327784","cross_references":{"pubmed":["38552208"],"doi":["10.1093/cid/ciae170"]}}